Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 3075-3077

  Meden, Harald ^a   Mielke, Stephan ^a   Marx, Dagmar ^a   Wuttke, Wolfgang ^a   Kuhn, Walther ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

C erbB 2; Hormonal treatment; Oncogene; p105; Serum

Indexed keywords

ONCOPROTEIN; SEX HORMONE;

CANCER PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; ONCOGENE C ERB; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADAL STEROID HORMONES; HUMANS; RECEPTOR, ERBB-2;

EID: 0030852397     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash DC) 235: 177-182, 1987
2. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: The neu oncogene: an erb-B-related gene encoding a 185.000-M tumour antigen. Nature 312: 513-516, 1984
3. Yamamoto T, Shantard I, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: An erb-B-related gene c-erbB-2 encodes a possible receptor protein similar to the epidermal growth factor receptor. Nature 319: 230-234, 1986
4. King, CR, Krauss, MH, DiFiore PP, Paik S, Kasprzyk, PG: Implications of erbB-2 overexpression for basic science and clinical medicine. Sem Cancer Biol 1: 329-338, 1990
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash DC) 244: 707-712, 1989
6. Marx D, Schauer A, Reiche C, May A, Ummenhofer AL, Reles A, Rauschecker H, Sauer R, Schumacher M: C-erbB-2-expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116: 15-20, 1990
7. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A: Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Intern J Gynecol Pathol 13: 45-53, 1994
8. Meden H, Marx D, Fattahi A, Rath W, Kron M, Wuttke W, Schauer A, Kuhn W: Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol 129: 378-381, 1994
9. Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells. SK-BR-3. J Biol Chemistry 266: 1716-1720, 1991
10. Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogawa M, Shiraishi M, Toyshima K, Yamamoto T: In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81: 489-494, 1990
11. Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, McKenzie S, Hayes S, Kufe D, DeLellis R, Naber R, Wolfe H: Detection and quantification of the human neu oncoprotein. J Tumor Marker Oncol 6: 53-72, 1991.
12. Leitzel K, Teramoto Y, Sampson D, Mauceri J, Langten BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A: Elevated soluble c-erbB-2 antigen levels in serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436-1443, 1992
13. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 119: 249-252, 1993